Mir-29 mimicry as a therapy for pulmonary fibrosis
Description: Project Narrative Idiopathic Pulmonary Fibrosis (IPF) is a fatal and devastating lung disease of unknown etiology with an average life expectancy of 3-5 years from initial diagnosis, and 40,000 patients die each year from IPF. The microRNA mir-29, a small non-coding RNAs that regulates the expression of many fibrosis related molecules, is decreased in expression in patients with IPF. The objective of this proposal is to develop microRNA replacement (mimicry) as a viable and novel therapy for this devastating disease and an objective that will have significant impact on the morbidity and mortality of many patients with IPF.
Funding type: cooperative_agreement
Funder scheme: UH2
Start date: 2014-09-22
End date: 2016-08-18
Investigator: NAFTALI KAMINSKI
Institution: YALE UNIVERSITY
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 34
Funder award ID: UH2HL123886
OpenAlex ID: G7456959975
